Regulus Therapeutics reports positive Phase 1b trial results for ADPKD treatment RGLS8429.
Regulus Therapeutics reported positive Phase 1b trial results for RGLS8429 in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Phase 1b Multiple-Ascending Dose (MAD) clinical trial demonstrated safety, tolerability, pharmacokinetics, and pharmacodynamics of the treatment. The stock price increased by 14%. Enrollment has begun for the fourth cohort, which will include up to 30 patients.
June 24, 2024
5 Articles